Drug Trial Radar · NCT00537420
A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects
Last checked: Nov 20, 2026Latest source record: Sep 15, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
551
Actual
Start
Oct 2007
Primary completion
Jul 2008
Study completion Sep 2008
Sponsor
- Lead sponsor
- Nastech Pharmaceutical Company, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 1, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the effect of nasal PYY3-36 on weight loss post 24 weeks of treatment.
Conditions
- Obesity
Interventions
Nasal PlaceboDrug
Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.
Placebo CapsuleDrug
Placebo capsules will be taken once daily with or without food.
PYY3-36Drug
Nasal PYY3-36, three times a day, 30 minutes before a meal for 24 weeks.
PYY3-36Drug
Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
PYY3-36Drug
Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
SibutramineDrug
Sibutramine will be taken once daily with or without food
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the effect of increasing nasal PYY3 36 dosing on weight loss post 24 weeks of treatmentTime frame: 24 Weeks
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Peoria, Arizona
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Phoenix, Arizona
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Anaheim, California
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Beverly Hills, California
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Carmichael, California
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Orange, California
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Sacramento, California
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
San Diego, California
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
San Diego, California
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
San Francisco, California
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Pembroke Pines, Florida
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Atlanta, Georgia
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Augusta, Georgia
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Evansville, Indiana
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Valparaiso, Indiana
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Baton Rouge, Louisiana
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Brooklyn Center, Minnesota
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Las Vegas, Nevada
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Manlius, New York
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Charlotte, North Carolina
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Raleigh, North Carolina
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Cleveland, Ohio
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Reading, Pennsylvania
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Greer, South Carolina
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Mt. Pleasant, South Carolina
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Austin, Texas
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
San Antonio, Texas
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Temple, Texas
For additional information regarding investigative sites for this trial, contact 1-425-415-3011
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.